Approved indications: Entecavir is approved to treat chronic hepatitis B virus infection in adults and children 2 years and older who have evidence of active viral replication and liver inflammation or histologic liver disease.

Off-label uses: Clinicians sometimes use entecavir to help prevent hepatitis B reactivation in people with chronic or past HBV infection who are receiving strong immunosuppressive therapy or chemotherapy, and as part of combination therapy for difficult, drug‑resistant HBV; evidence for these uses comes from clinical studies and expert guidelines and is generally moderate to high in quality.

Efficacy expectations: HBV DNA levels usually start to fall within weeks, with liver enzyme (ALT) improvement over a few months; many nucleoside‑naïve patients achieve undetectable HBV DNA and normalization of ALT within 1 year, though loss of hepatitis B surface antigen (HBsAg) and complete functional cure remain uncommon and long‑term therapy is often needed.

Comparison to similar drugs: Entecavir is a potent first‑line nucleos(t)ide analogue with a high barrier to resistance in nucleoside‑naïve patients and efficacy comparable to tenofovir; tenofovir is often preferred in patients with prior lamivudine resistance or HIV co‑infection, whereas entecavir may be favored in some patients with kidney or bone concerns where tenofovir disoproxil may be less desirable.

Typical dosing and how to take: For adults who are nucleoside‑naïve, the usual dose is 0.5 mg by mouth once daily; for adults with prior lamivudine resistance or decompensated liver disease, the typical dose is 1 mg once daily. Children 2 years and older receive once‑daily weight‑based doses using the oral solution or tablets up to 0.5 mg (nucleoside‑naïve) or 1 mg (lamivudine‑experienced). Entecavir should be taken on an empty stomach, at least 2 hours before or after a meal, at about the same time each day, and swallowed with water (or measured carefully if using the oral solution).

Special dosing instructions: People with reduced kidney function usually need lower or less frequent doses based on creatinine clearance; no adjustment is typically needed for mild liver impairment, but those with advanced cirrhosis require close supervision. Treatment is often long term, and the medicine should not be stopped or changed without instructions from the prescribing clinician.

Missed dose: If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped; two doses should not be taken at the same time to make up for a missed dose.

Overdose: In case of suspected overdose, the person should contact a poison control center (such as 1‑800‑222‑1222 in the United States) or seek emergency medical care immediately, bringing the medication container if possible.

Common side effects: The most frequent side effects include headache, fatigue, dizziness, nausea, diarrhea, and trouble sleeping; these are usually mild to moderate, often appear in the first days to weeks of treatment, and many patients have few or no noticeable side effects.

Serious or rare adverse effects: Rare but serious reactions include lactic acidosis and severe liver enlargement with fat buildup, severe flares of hepatitis (especially after stopping the drug), worsening liver function in people with advanced liver disease, and the development of resistant HIV if entecavir is used alone in patients with unrecognized or untreated HIV infection; sudden jaundice, deep fatigue, shortness of breath, abdominal pain, or dark urine need urgent medical attention.

Warnings and precautions: Dose adjustment is needed in reduced kidney function; people with decompensated cirrhosis or a history of liver transplantation require close monitoring; stopping entecavir should be done only under medical supervision because of the risk of hepatitis flares; in pregnancy and breastfeeding, available human data are limited but generally reassuring, and the drug is used when the expected benefits outweigh potential risks, often with specialist guidance; it is approved for children 2 years and older, with weight‑based dosing.

Relative safety: Compared with some older antivirals for HBV, entecavir has a favorable safety profile and low resistance rates in treatment‑naïve patients, and it generally causes less kidney and bone toxicity than tenofovir disoproxil, though careful monitoring is still important in patients with existing kidney disease.

Reporting and safety updates: Patients and clinicians can report suspected side effects to the FDA MedWatch program or the manufacturer, and can check FDA Drug Safety Communications or updated prescribing information for the latest safety warnings.

Drug and supplement interactions: Entecavir is not significantly metabolized by common liver enzyme systems, so it has relatively few classic drug–drug interactions, but medicines that affect kidney function (such as certain diuretics, NSAIDs, or other antivirals eliminated by the kidneys) may change entecavir levels or increase toxicity risk, and high‑dose or multiple nephrotoxic drugs should be used cautiously.

Food, alcohol, and procedures: Food can reduce entecavir absorption, so it is recommended to take it on an empty stomach; alcohol should be limited or avoided because it can worsen liver damage in people with hepatitis B. There are no specific interactions with imaging contrast dyes or common diagnostic procedures, but overall kidney and liver function should be considered when other agents are used.

Precautions and co-medications: People with chronic hepatitis B and HIV co‑infection should not receive entecavir alone, because it can select for HIV resistance mutations; instead, it should be used only as part of a fully suppressive antiretroviral regimen. Use with caution in patients with decompensated cirrhosis, prior liver transplantation, or significant kidney disease, and ensure careful review of all prescription medicines, over‑the‑counter drugs, and herbal supplements.

Monitoring needs: During treatment, clinicians typically monitor HBV DNA levels, liver enzymes, and clinical status every few months, check kidney function periodically (especially in those at risk), and continue to monitor liver tests for several months after stopping therapy to detect hepatitis flares early.

Q: Does entecavir cure hepatitis B or will I need to take it for life?
A: Entecavir usually does not completely cure hepatitis B; it controls the virus while you are taking it, and many people need long‑term or even lifelong therapy unless they achieve a strong immune response and meet specific criteria to stop safely.

Q: How long does it take for entecavir to start working?
A: The amount of virus in your blood (HBV DNA) often begins to drop within a few weeks, but lab tests over several months are needed to see the full effect and to confirm that the medicine is working well.

Q: Is it safe to drink alcohol while taking entecavir?
A: Alcohol does not directly interfere with entecavir, but because both alcohol and hepatitis B can damage the liver, most clinicians advise avoiding or strictly limiting alcohol while on treatment.

Q: Can I take entecavir during pregnancy or while breastfeeding?
A: Entecavir has limited but generally reassuring pregnancy and breastfeeding safety data; decisions are individualized, and your clinician may weigh its benefits against potential risks or consider alternative antivirals with more pregnancy experience.

Q: What should I do if I miss a dose of entecavir?
A: Take the missed dose as soon as you remember unless it is almost time for your next dose, in which case skip the missed one and continue your regular schedule without doubling up.

Q: How is entecavir different from tenofovir for hepatitis B?
A: Both are powerful first‑line medicines for chronic hepatitis B, but tenofovir is often preferred in patients with prior lamivudine resistance or HIV co‑infection, while entecavir may be favored in some people with kidney or bone concerns; your clinician chooses based on your overall health and treatment history.

Storage: Store entecavir tablets or oral solution at room temperature (about 68–77°F / 20–25°C), in a tightly closed original container, away from excess heat and moisture, and out of reach of children and pets.

Disposal: Use a local medicine take‑back program when possible; if none is available, mix unused medicine (not oral solution in the bottle) with an unappealing substance such as coffee grounds or cat litter, place in a sealed bag or container, and throw it in the household trash, after removing or scratching out personal information on prescription labels.